Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.
复制标题
难治性卵巢癌的新治疗策略：透明细胞癌和粘液癌。
DOI：
10.3390/cancers13236120
复制
发表时间：
2021-12-04
期刊：
影响因子：
5.2
通讯作者：
Itamochi H
中科院分区：
文献类型：
--
作者：
Shoji T;Tatsuki S;Abe M;Tomabechi H;Takatori E;Kaido Y;Nagasawa T;Kagabu M;Baba T;Itamochi H
卵巢透明细胞癌和粘液癌对化疗不敏感。这可以通过致癌机制和分子生物学特征来解释。尽管临床研究已经对细胞毒性抗癌药物的化疗进行了评价，但没有一种治疗效果优于紫杉醇+卡铂治疗。近年来，人们的注意力一直集中在用分子靶向药物和免疫检查点抑制剂进行治疗，这些药物靶向新发现的生物标志物，并且已经计划了许多关于此类治疗的临床研究。卵巢癌是妇科癌症中预后最差的。特别是，透明细胞癌和粘液癌对化疗不太敏感。建立新的治疗方法是必要的，以改善这些癌症的治疗结果。在先前的临床研究中，使用细胞毒性抗癌药物的化疗未能证明比紫杉醇+卡铂治疗更好的治疗结局。近年来，人们的注意力集中在分子靶向药物和免疫检查点抑制剂的治疗上，这些药物靶向新发现的生物标志物。需要解决的问题包括最合适的治疗组合，确定可能从每种治疗中受益的患者，以及如何将结果纳入卵巢透明细胞癌和粘液癌的护理标准。在这篇文章中，我们已经审查了最有前途的治疗卵巢透明细胞癌和粘液癌，这被认为是难治性的，重点是治疗目前正在研究的临床研究。
Ovarian clear cell and mucinous carcinomas are less sensitive to chemotherapy. This can be explained by carcinogenic mechanisms and molecular biological features. Although chemotherapy with cytotoxic anticancer drugs has been evaluated by clinical studies, none have achieved better treatment outcomes than paclitaxel + carboplatin therapy. In recent years, attention has been focused on treatment with molecular target drugs and immune checkpoint inhibitors that target newly identified biomarkers, and many clinical studies on such treatments have been planned. Ovarian cancer has the worst prognosis among gynecological cancers. In particular, clear cell and mucinous carcinomas are less sensitive to chemotherapy. The establishment of new therapies is necessary to improve the treatment outcomes for these carcinomas. In previous clinical studies, chemotherapy with cytotoxic anticancer drugs has failed to demonstrate better treatment outcomes than paclitaxel + carboplatin therapy. In recent years, attention has been focused on treatment with molecular target drugs and immune checkpoint inhibitors that target newly identified biomarkers. The issues that need to be addressed include the most appropriate combination of therapies, identifying patients who may benefit from each therapy, and how results should be incorporated into the standard of care for ovarian clear cell and mucinous carcinomas. In this article, we have reviewed the most promising therapies for ovarian clear cell and mucinous carcinomas, which are regarded as intractable, with an emphasis on therapies currently being investigated in clinical studies.
登录
查看更多内容
影响因子：
4.7
作者：
Chan JK;Brady W;Monk BJ;Brown J;Shahin MS;Rose PG;Kim JH;Secord AA;Walker JL;Gershenson DM
通讯作者：
Gershenson DM
DOI：
10.1158/1078-0432.ccr-09-0401
发表时间：
2009-07-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Baba Y;Nosho K;Shima K;Freed E;Irahara N;Philips J;Meyerhardt JA;Hornick JL;Shivdasani RA;Fuchs CS;Ogino S
通讯作者：
Ogino S
通过荧光共振能量转移成像，PI3K/MTOR和MEK抑制（SAR245409和Pimasertib）组合的协同抗肿瘤作用（SAR245409和Pimasertib）在粘液卵巢癌细胞中。
影响因子：
--
作者：
Inaba K;Oda K;Aoki K;Sone K;Ikeda Y;Miyasaka A;Kashiyama T;Fukuda T;Makii C;Arimoto T;Wada-Hiraike O;Kawana K;Yano T;Osuga Y;Fujii T
通讯作者：
Fujii T
影响因子：
4.7
作者：
Gemignani, ML;Schlaerth, AC;Boyd, J
通讯作者：
Boyd, J
影响因子：
9.7
作者：
Hanski, C;Tiecke, F;Riecken, EO
通讯作者：
Riecken, EO